Intranasal delivery, also known as intranasal drug delivery, is a non-invasive method of administering drugs locally or systemically to the brain and systemic circulation by passing medications through the nasal cavities and membranes. This delivery route provides direct access to the brain, circumvents first-pass metabolism, and offers a convenient alternative to oral, injectable, and implantable drug administration methods.
Advantages of Intranasal Delivery
One of the major advantages of Intranasal Drug Delivery is that it allows for rapid drug absorption and onset of clinical effects. Drugs administered intranasally are absorbed through the nasal mucosa and carried to the brain via neuronal and vascular pathways to produce a fast therapeutic response within 5-15 minutes. This quick absorption circumvents gastric degradation and first-pass metabolism in the liver associated with oral administration of drugs.
Intranasal delivery also provides a non-invasive alternative to injections. Many patients prefer sprays or drops in the nose over hypodermic needles due to fear of pain from injections. This increases patient compliance for self-administration of medications for conditions like migraine headaches, seizures, and pain. The nasal route also avoids fluctuations in drug bioavailability associated with oral drugs due to factors like food intake.
Anatomy Supporting Rapid Drug Uptake
The nasal cavity has a highly vascularized and permeable mucosal membrane with a surface area of about 150 cm2 that enhances drug absorption. The nasal mucosa is protected by an aqueous layer of mucus that lubricates and provides a medium for solubilizing and transporting drugs to the underlying tissues. This anatomy, along with an extensive network of venous plexuses, capillaries and arterial vessels supplying the area, facilitates the rapid uptake of drugs administered intranasally to enter the systemic circulation.
The nasal route also provides indirect access to the brain via connections between the nasal cavity and the central nervous system pathways like the olfactory and trigeminal nerves. Drugs can be transported from the nose to the brainstem, thalamus and cortex within minutes, bypassing the blood-brain barrier, to produce a swift therapeutic response. This neural delivery pathway potentially allows targeting of therapeutics to the brain for conditions like Alzheimer's, Parkinson's diseases and brain tumors.
Formulations for Intranasal Administration
Various pharmaceutical formulation types have been developed for intranasal delivery depending on the properties of the active drug. The most common include solutions, suspensions, emulsions, gels and microsphere-based systems. Solutions and suspensions utilize the drug substance dissolved or suspended in an aqueous vehicle containing humectants like glycerin or sorbitol to retain moisture.
Emulsions help incorporate lipophilic drugs in an oil-water system containing surfactants. Mucoadhesive gels and ointment-based systems increase contact time with the nasal mucosa using polymers. Microsphere and nanoparticle carriers encapsulate the drug payload to modify drug pharmacokinetics and control its release. Choice of carriers like liposomes, dendrimers and polymeric nanospheres also facilitate drug penetration across the nasal epithelium. Such delivery systems aim to maximize drug absorption and bioavailability via the intranasal route.
Applications of Intranasal Delivery
Intranasal administration presents an attractive option for time-critical drug delivery in emergency conditions including treatment of seizures, migraine attacks, pain crises, hypoglycemia and resuscitation agents. Some drugs that are commonly administered through the nasal route include naloxone for opioid overdose, midazolam for seizures, sumatriptan for migraine and intranasal insulin for diabetes.
The intranasal route is also being evaluated for delivery of large molecule biotherapeutics like peptides, proteins and vaccines that are traditionally challenging to administer. Recent approvals include nasal vaccines for influenza virus and oxytocin nasal spray. Development efforts are underway to expand applications of intranasal delivery for treatment of neurological conditions like strokes, depression, and nasal delivery of gene therapy vectors for brain diseases.
Commercialization and Regulatory Considerations
Large pharmaceutical companies like Baxter, Pfizer, Liquidia, OptiNose have commercially successful intranasal drug products in the market. However, the real potential of intranasal delivery is yet to be fully realized, with considerable ongoing research focused on expanding its applications. Regulatory guidance from health authorities like FDA regarding formulation and characterization requirements specific to this delivery route need to be established to streamline product development.
Standardization of preclinical testing parameters evaluating drug permeability, regional brain and systemic exposure levels will help scientific community efficiently translate intranasal formulations into the clinic. With enhanced formulation technology and clinical data supporting safety and efficacy, more intranasal drugs hold promise to be approved in the coming years to meet diverse patient, healthcare and market needs via this non-invasive delivery route.
intranasal delivery presents an attractive option for systemic as well as localized delivery to the brain. Advancements in formulation and delivery device technologies along with continued demonstration of clinical benefits can help this administration route achieve its full potential in the coming years for diverse therapeutic applications.
Get this Report in Japanese Language:
Get this Report in Korean Language:
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment